CD274 and non-small cell lung carcinoma: The PACIFIC trial, a phase 3 study that compared the anti-programmed death-ligand 1 (PD-L1) antibody durvalumab with placebo as consolidation therapy after CCRT, is a practice-changing study as it demonstrated that consolidation durvalumab significantly improved overall survival (OS) in patients with unresectable stage III NSCLC [3].